Twist Bioscience Co. (NASDAQ:TWST) Receives $52.80 Average Price Target from Analysts

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the ten research firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $52.80.

A number of research analysts recently issued reports on the company. Barclays cut their price target on Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a report on Thursday, April 10th. Scotiabank reaffirmed an "outperform" rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Robert W. Baird increased their price target on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an "outperform" rating in a research note on Tuesday, February 4th. JPMorgan Chase & Co. increased their price objective on Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a research report on Tuesday, February 4th. Finally, Guggenheim set a $50.00 target price on Twist Bioscience in a research report on Friday, March 28th.

Insider Buying and Selling at Twist Bioscience

In other news, Director Robert Chess sold 2,940 shares of the company's stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $53.13, for a total value of $156,202.20. Following the completion of the sale, the director now directly owns 18,173 shares of the company's stock, valued at $965,531.49. This represents a 13.93 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Emily M. Leproust sold 5,200 shares of Twist Bioscience stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $49.35, for a total transaction of $256,620.00. Following the transaction, the chief executive officer now directly owns 667,318 shares in the company, valued at $32,932,143.30. The trade was a 0.77 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 22,796 shares of company stock valued at $1,077,383. 3.01% of the stock is currently owned by company insiders.

Institutional Trading of Twist Bioscience

Several hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its holdings in shares of Twist Bioscience by 3.4% in the fourth quarter. Vanguard Group Inc. now owns 5,807,183 shares of the company's stock worth $269,860,000 after acquiring an additional 189,791 shares in the last quarter. ARK Investment Management LLC grew its position in shares of Twist Bioscience by 4.4% in the 4th quarter. ARK Investment Management LLC now owns 5,595,865 shares of the company's stock valued at $260,040,000 after purchasing an additional 237,772 shares during the period. Thrivent Financial for Lutherans increased its stake in Twist Bioscience by 54.6% during the 4th quarter. Thrivent Financial for Lutherans now owns 1,505,753 shares of the company's stock worth $69,972,000 after purchasing an additional 532,040 shares in the last quarter. Geode Capital Management LLC raised its holdings in Twist Bioscience by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 1,374,667 shares of the company's stock worth $63,895,000 after buying an additional 6,908 shares during the period. Finally, First Light Asset Management LLC acquired a new stake in Twist Bioscience during the 4th quarter worth approximately $56,984,000.

Twist Bioscience Price Performance

TWST stock traded up $0.68 during trading on Friday, hitting $37.62. 1,123,661 shares of the stock traded hands, compared to its average volume of 984,550. The stock has a market cap of $2.24 billion, a price-to-earnings ratio of -11.13 and a beta of 2.34. Twist Bioscience has a one year low of $29.76 and a one year high of $60.90. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. The company has a 50 day simple moving average of $39.95 and a 200 day simple moving average of $44.28.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.62) by $0.09. The company had revenue of $88.70 million during the quarter, compared to analysts' expectations of $86.96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. Twist Bioscience's quarterly revenue was up 24.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.75) earnings per share. Equities analysts expect that Twist Bioscience will post -2.12 EPS for the current fiscal year.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.